Table 3 Bivalent HPV16 vaccine efficacy against incident, 6-month persistent HPV16 infections among women who were HPV DNA negative through year 2, stratified by HPV16 serological status at time of vaccination and dose.
From: HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial
Vaccine | Control | Vaccine efficacy | |||
|---|---|---|---|---|---|
Group | n/N | Attack rate per 1000 women | n/N | Attack rate per 1000 women | % (95% CI) |
HPV16 DNA negative and HPV16 seronegative | |||||
One-dose | 0/115 | 0.0 (0.0–25.7) | 8/101 | 79.2 (37.5–144.8) | 100.0% (60.1–100.0%) |
Three-dose | 4/1965 | 2.0 (0.6–4.9) | 84/1898 | 44.3 (35.7–54.2) | 95.4 (88.5–98.6%) |
HPV16 DNA negative and HPV16 seropositive | |||||
One-dose | 0/41 | 0.0 (0.0–70.5) | 2/32 | 62.5 (10.6–191.5) | 100.0% (−171.0 to 100.0%) |
Three-dose | 1/582 | 1.7 (0.1–8.4) | 15/580 | 25.9 (15.1–41.4) | 93.4% (62.8–99.7%) |
